- Patients with opioid use disorder (OUD) who received an initial buprenorphine supply for ≤15 days or an initial daily dose of ≤4 mg were more likely to discontinue treatment.
- Receiving a ≥16 days’ supply of buprenorphine was associated with reduced risk for adverse events.
Why this matters
- Although the use of buprenorphine treatment is becoming more common, treatment discontinuation rates are high.
- 17,158 individuals who had initiated buprenorphine treatment for OUD were identified.
- Funding: National Institute of Mental Health; National Institute on Drug Abuse.
- 10% of initial prescriptions had a daily dose ≤4 mg; 31%, 27%, 9%, and 33% of prescriptions were for ≤7, 8-15, 16-27, and ≥28 days' supply, respectively.
- 55% discontinued buprenorphine within 180 days and 13% experienced ≥1 opioid-related event within 360 days.
- Treatment discontinuation was more likely (P<.01 among individuals who received: style="list-style-type:circle;">
- a daily dose of ≤4 mg (aOR, 1.79) and
- an initial prescription for ≤15 days vs ≤28 days (≤7 days: aOR, 1.32; 8-15 days: aOR, 1.22).
- Findings to be interpreted with caution.
- Findings may not be generalizable.
Coauthored with Chitra Ravi, MPharm